Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 24, 2015, Pages 4906-4919

  Giacoppo, S ^a   Rajan, T Soundara ^a   Galuppo, M ^a   Pollastro, F ^b   Grassi, G ^c   Bramanti, P ^a   Mazzon, E ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c CRA Experimental Institute for Industrial Crops   (Italy)

Author keywords

Apoptosis; Cannabidiol; Experimental multiple sclerosis; Mitochondrial permeability; Non psychotropic cannabinoid

Indexed keywords

CANNABIDIOL; CANNABIS; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PHENYLTERPENOID DELTA 9 TETRAHYDROCANNABINOL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG; PLANT EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL TEST; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MULTIPLE SCLEROSIS; NEEDLE TEST; NERVE CELL; NONHUMAN; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; PHYTOTHERAPY;

ANIMALS; APOPTOSIS; CANNABIDIOL; CANNABIS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84966440434     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. TRAPP BD, NAVE KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-269.
2. SCHWAB N, SCHNEIDER-HOHENDORF T, WIENDL H. Therapeutic uses of anti-alpha4-integrin (anti-VLA-4) antibodies in multiple sclerosis. Int Immunol 2015; 27: 47-53.
3. MA VY, CHAN L, CARRUTHERS KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil 2014; 95: 986-995.
4. ZAGMUTT FJ, CARROLL CA. Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. Int J Neurosci 2015; 125: 798-807.
5. MCKEAGE K. Glatiramer Acetate 40 mg/mL in relapsing-remitting multiple sclerosis: a review. CNS Drugs 2015; 29: 425-32.
6. SWEET BV. Natalizumab update. Am J Health Syst Pharm 2007; 64: 705-716.
7. FUNG W, ROBERTSON NP. Natalizumab in MS: JC antibody index. J Neurol 2015; 262: 492-494.
8. Namjooyan F, Ghanavati R, Majdinasab N, Jokari S, Janbozorgi M. Uses of complementary and alternative medicine in multiple sclerosis. J Tradit Complement Med 2014; 4: 145-152.
9. KES VB, CESARIK M, MATOVINA LZ, ZAVOREO I, CORIC L, DRNASIN S, DEMARIN V. The role of complementary and alternative medicine in therapy of multiple sclerosis. Acta Clin Croat 2013; 52: 464-471.
10. GALLIEN P, GICH J, SANCHEZ-DALMAU BF, FENEBERG W. Multidisciplinary management of multiple sclerosis symptoms. Eur Neurol 2014; 72: 20-25.
11. PAGNINI F, BOSMA CM, PHILLIPS D, LANGER E. Symptom changes in multiple sclerosis following psychological interventions: a systematic review. BMC Neurol 2014; 14: 222.
12. GERTSCH J, PERTWEE RG, DI MARZO V. Phytocannabinoids beyond the Cannabis plant-do they exist? Br J Pharmacol 2012; 160: 523-529
13. HAZEKAMP A, WARE MA, MULLER-VAHL KR, ABRAMS D, GROTENHERMEN F. The medicinal use of cannabis and cannabinoids - an international cross-sectional survey on administration forms. J Psychoactive Drugs 2013; 45: 199-210
14. STERN CA, GAZARINI L, VANVOSSEN AC, ZUARDI AW, GALVE-ROPERH I, GUIMARAES FS, TAKAHASHI RN, BERTOGLIO LJ. Delta-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. Eur Neuropsychopharmacol 2015; 25: 958-965.
15. ENGLAND TJ, HIND WH, RASID NA, O'SULLIVAN SE. Cannabinoids in experimental stroke: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2015; 35: 348-358.
16. HILL AJ, WILLIAMS CM, WHALLEY BJ, STEPHENS GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 2012; 133: 79-97.
17. MOLDZIO R, PACHER T, KREWENKA C, KRANNER B, NOVAK J, DUVIGNEAU JC, RAUSCH WD. Effects of cannabinoids Delta(9)-tetrahydrocannabinol, Delta(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures. Phytomedicine 2012; 19: 819-824.
18. MCALLISTER SD, SOROCEANU L, DESPREZ PY. The antitumor activity of plant-derived non-psychoactive cannabinoids. J Neuroimmune Pharmacol 2015; 10: 255-267.
19. GIACOPPO S, MANDOLINO G, GALUPPO M, BRAMANTI P, MAZZON E. Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules 2014; 19: 18781-18816
20. MECHA M, FELIU A, INIGO PM, MESTRE L, CARRILLO-SALINAS FJ, GUAZA C. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol Dis 2013: 59: 141-150.
21. KOZELA E, LEV N, KAUSHANSKY N, EILAM R, RIMMERMAN N, LEVY R, BEN-NUN A, JUKNAT A, VOGEL Z. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol 2011; 163: 1507-1519.
22. BURSTEIN S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem 2015; 23: 1377-1385.
23. BITTNER S, AFZALI AM, WIENDL H, MEUTH SG. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. J Vis Exp 2014; 15.
24. TAGLIALATELA-SCAFATI O, PAGANI A, SCALA F, DE PETROCELLIS L, DI MARZO V, GRASSI G, APPENDINO G. Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp. Eur J Org Chem 2010; 2010: 2067-2072.
25. RODRIGUES DH, VILELA MC, BARCELOS LS, PINHO V, TEIXEIRA MM, TEIXEIRA AL. Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 2010; 222: 90-94.
26. CAGNOL S, CHAMBARD JC. ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J 2010; 277: 2-21
27. ROSS AP, HACKBARTH N, ROHL C, WHITMYRE K. Effective multiple sclerosis management through improved patient assessment. J Neurosci Nurs 2008; 40: 150-157
28. PRYCE G, RIDDALL DR, SELWOOD DL, GIOVANNONI G, BAKER D. Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. J Neuroimmune Pharmacol 2015; 10: 281-292.
29. FU W, TAYLOR BK. Activation of cannabinoid CB receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neurosci Lett. 2015; 595: 1-6.
30. DAVIS MP. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Investig Drugs 2014; 23: 1123-1140.
31. D'SOUZA SD, BONETTI B, BALASINGAM V, CASHMAN NR, BARKER PA, TROUTT AB, RAINE CS, ANTEL JP. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184: 2361-2370.
32. HARRIS MH, THOMPSON CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000; 7: 1182-1191.
33. SCHEIBYE-KNUDSEN M, FANG EF, CROTEAU DL, WILSON DM, 3RD, BOHR VA. Protecting the mitochondrial powerhouse. Trends Cell Biol 2015; 25: 158-170.
34. RIMMERMAN N, BEN-HAIL D, PORAT Z, JUKNAT A, KOZELA E, DANIELS MP, CONNELLY PS, LEISHMAN E, BRADSHAW HB, SHOSHAN-BARMATZ V, VOGEL Z. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis 2013; 4: e949.
35. HAGMAN S, KOLASA M, BASNYAT P, HELMINEN M, KAHONEN M, DASTIDAR P, LEHTIMAKI T, ELOVAARA I. Analysis of apoptosis-related genes in patients with clinically isolated syndrome and their association with conversion to multiple sclerosis. J Neuroimmunol 2015; 280: 43-48.
36. CUDRICI C, NICULESCU T, NICULESCU F, SHIN ML, RUS H. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: protection of oligodendrocytes from apoptosis by complement. J Rehabil Res Dev 2006; 43: 123-132.
37. MECHA M, TORRAO AS, MESTRE L, CARRILLO-SALINAS FJ, MECHOULAM R, GUAZA C. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis 2012; 3: e331.
38. ROUX PP, BLENIS J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-344.
39. CHAI YL, CUI J, SHAO N, SHYAM E, REDDY P, RAO VN. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene 1999; 18: 263-268.
40. KLUGER B, TRIOLO P, JONES W, JANKOVIC J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord 2015; 30: 313-327.